

Listing of Claims

The following list of claims will replace all prior versions and listings of claims in the application.

1-15. (Canceled)

16. (Currently Amended) A method of reducing endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need thereof,

wherein said endothelial injury is caused by a chemotherapeutic agent and said erythropoietin is administered prior to initial administration of said chemotherapeutic agent.

17-21. (Canceled)

22. (Previously Presented) A method according to claim 16, wherein said erythropoietin is administered intravenously.

23-30. (Canceled)

31. (Currently Amended) A method of treating endothelial injury in a subject, comprising intravenously administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

wherein said effective endothelial-protecting amount of erythropoietin reduces or prevents the suppression of endothelial growth associated with endothelial injury caused by a chemotherapeutic agent and said erythropoietin is administered prior to initial administration of said chemotherapeutic agent.

32. (Currently Amended) A method of treating endothelial injury in a subject, comprising intravenously administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

wherein said effective endothelial-protecting amount of erythropoietin increases the numbers of viable endothelial cells following endothelial injury caused by a

chemotherapeutic agent and said erythropoietin is administered prior to initial administration of said chemotherapeutic agent.

33. (Previously Presented) A method according to claim 16, wherein said erythropoietin is administered in an amount of from about 100 Units per kilogram to about 200 Units per kilogram.

34-41. (Canceled)

42. (Previously Presented) A method of claim 16, wherein said chemotherapeutic agent is cisplatin.

43. (Currently Amended) A method of reducing endothelial injury in a subject, comprising intravenously administering an effective endothelial-protecting amount of erythropoietin to said subject in need thereof,

wherein said endothelial injury is caused by cisplatin and said erythropoietin is administered in an amount less than about 750 U/kg and prior to initial administration of said cisplatin.